Although we observed an increasing trend of serum Lcn-2 levels in MS patients compared to HDs (Figure 4A), fecal rather than serum Lcn-2 levels were significantly associated with MS (Figures 4B, C). Here, LCN2 is linked to myeloid sarcoma.